evolving and unclear. Current investigative efforts are being targeted towards combination therapy and patient selection. For example, carbonic anhydrase IX expression has been associated with a higher ORR with IL-2 in retrospective analyses, identifying it as a potential independent prognostic marker in patients with mRCC, although its utility in this setting has been questioned. [17] [18] [19] 
Nephrectomy
Cytoreductive nephrectomy followed by immunotherapy is recommended for patients with mRCC who have potentially resectable primary tumours. This is based on the results of two clinical studies that investigated the benefit of cytoreductive nephrectomy followed by cytokine therapy. These prospective, randomised trials from the Southwest Oncology Group (SWOG) and the European Organisation for the Research and Treatment of Cancer (EORTC) evaluated nephrectomy followed by IFN-α compared with IFN-α alone. 20, 21 In both studies, overall survival was significantly longer when nephrectomy was part of the treatment strategy (SWOG 11.1 versus
months, EORTC 17 versus seven months). A combined analysis of
these studies revealed a median survival advantage of 5.8 months when nephrectomy was followed by IFN-α (p=0.002). 22 Patients most likely to benefit from cytoreductive therapy are those with good performance status, good prognostic features and limited metastatic burden. 23 However, the treatment paradigm for mRCC is evolving and these studies pre-date the advent of targeted therapies. The potential survival benefits of nephrectomy in the context of targeted agents remain to be determined. Ongoing studies, such as the European phase III Clinical Trial to Assess the Importance of Nephrectomy (CARMENA; clinicaltrials.gov identifier NCT00930033), are exploring the role of nephrectomy in patients exposed to targeted treatment.
Targeted Therapy
An increased understanding of the molecular biology of mRCC has resulted in the identification of several viable therapeutic targets and novel agents that inhibit these pathways, leading to major improvements in the treatment options for mRCC (see Table 1 ). These factor that regulates the expression of pro-angiogenic factors such as VEGF, providing a rationale for targeting this pathway. 24, 25 The mTOR pathway is a central component of multiple tumour-promoting intracellular signalling pathways, 26 including HIF expression, and activation of this pathway has been documented in mRCC. 27 
Multikinase Inhibitors Sunitinib
Sunitinib is a tyrosine kinase inhibitor (TKI) that targets VEGFR2, platelet-derived growth factor receptor (PDGFR), FMS-like tyrosine kinase 3 (FLT-3) and c-KIT. 28, 29 Sunitinib is administered as an oral dose of 50mg once a day for four weeks followed by a two-week break.
Two multicentre phase II studies of sunitinib in mRCC patients who had failed previous cytokine therapy demonstrated similar results:
partial responses were reported in 40 and 34% in the two studies, respectively, and median progression-free survival (PFS) was 8.8 and 8.3 months, respectively. 30, 31 Fatigue was the most common adverse event in both studies.
The favourable results of these phase II studies led to a phase III trial of sunitinib versus IFN-α as first-line therapy. 32 This study recruited 750 treatment-naïve patients to repeated six-week cycles of sunitinib or IFN-α. Over 90% of patients recruited to the study had a favourable or intermediate prognosis and 90% had undergone prior nephrectomy. Kidney Cancer 
Sorafenib
Sorafenib is an oral TKI that targets the receptor tyrosine kinases VEGFR2, VEGFR3, FLT3, c-KIT and PDGFR and the non-receptor serine/threonine kinase RAF1, a major protein of the mitogen-activated protein kinase (MAPK) pathway. 36 Therefore, sorafenib is able to target both tumour angiogenesis and proliferation. Based on the results of a pivotal phase III randomised trial, sorafenib is recommended for the second-line treatment of mRCC following cytokine therapy. 37 In this study, 903 patients who had either received or were ineligible for cytokine therapy were randomised to receive sorafenib (at a dose of 400mg twice daily) or placebo; this dose of sorafenib was previously shown to be effective in a randomised phase II trial in mRCC. 38 A planned interim analysis of PFS in this phase III study showed a statistically significant advantage in the sorafenib arm (5.5 versus 2.8 months, HR 0.44; p<0.01). The ORR was also significantly higher in the sorafenib arm compared with placebo (10 versus 2%; p<0.001). 37 As a consequence of these results, placebo patients were permitted to cross-over to sorafenib. A significant survival advantage was seen with sorafenib in a per-protocol analysis adjusting for cross-over (17.8 versus 14.3 months, HR 0.78; p=0.0287). 39 Adverse events were generally manageable: diarrhoea, rash, fatigue and hand-foot skin reactions were the most common adverse events associated with sorafenib. Hypertension and cardiac ischaemia were rare serious adverse events that were more common in patients receiving sorafenib than in those receiving placebo.
In the first-line mRCC setting, a randomised phase II study of 189 patients demonstrated no difference in median PFS with sorafenib treatment compared with IFN-α (5.7 and 5.6 months, respectively),
although sorafenib-treated patients demonstrated greater rates of tumour size reduction, better quality of life and improved tolerability. 40 Finally, two phase II studies investigating the combination of sorafenib and IFN-α in mRCC demonstrated an ORR of 19 and 33%, respectively, and an encouraging median PFS (seven and 10 months, respectively). 41, 42 However, increased toxicities with the combination regimen compared with either drug alone was a concern in both of these studies.
Pazopanib
Pazopanib is an inhibitor of several kinases, including VEGFR1, -2 and prognostic score) 52 were randomised to receive temsirolimus (25mg Treatment Strategies in Metastatic Renal Cell Carcinoma Rash, peripheral oedema, hyperglycaemia and hyperlipidaemia were more common in the temsirolimus group, whereas asthenia was more common in the IFN-α group. Fewer patients experienced serious adverse events in the temsirolimus group compared with the IFN-α group. This study demonstrated that temsirolimus is a suitable option for the treatment of poor-prognosis mRCC patients and is recommended as a first-line therapy in this setting.
Everolimus
Everolimus is another mTOR inhibitor that is available for the treatment of patients with mRCC. Unlike the intravenously administered temsirolimus, everolimus is orally active. Everolimus demonstrated encouraging antitumour activity in a phase II study of patients with previously treated mRCC. 54 A subsequent phase III trial randomised 410 patients with mRCC whose disease had progressed on sunitinib, sorafenib or both (prior therapy with cytokines or bevacizumab was also allowed) to receive either everolimus (10mg once daily) or placebo. 55 The trial was stopped early after a second interim analysis had shown a significant difference in the primary end-point of PFS between the two groups (median four versus 1.9 months, HR 0.30; p<0.0001). An updated analysis showed that this significant PFS benefit was maintained during an additional 4.5 months of blinded follow-up (median 4.9 versus 1.9 months, HR 0.33; p<0.001). 56 This PFS benefit was maintained across all MSKCC riskclassification groups. The ORR with everolimus treatment was modest (1.8% in the updated analysis), suggesting that the effect of everolimus on PFS is the result of disease stabilisation. There was no significant difference in median overall survival between the arms (14.8 versus 14.4 months for everolimus and placebo, respectively, HR 0.87; p=0.162), although the survival results were likely to have been confounded by the majority of patients (80%) in the placebo arm who switched therapy following disease progression. 56 According to a post hoc exploratory analysis correcting for this cross-over effect, the corrected placebo overall survival was 10 months, a difference of 4.8 months compared with the observed everolimus overall survival. 56 Adverse events reported with everolimus treatment were mostly grade 1 or 2. The most common events were stomatitis, rash, fatigue or asthenia and diarrhoea. Based on these data, the latest European Association of Urology (EAU) and NCCN (category 1 recommendation) guidelines recommend everolimus for the second-line treatment of mRCC after prior treatment with VEGF TKI therapies.
Sequencing Targeting Agents
Sequential therapy with targeted agents could potentially further improve outcomes in patients with mRCC. A sequential strategy could allow a treatment regimen to be established whereby patients are maintained on a continuum of treatments without tumour progression. Furthermore, targeting different pathways through sequential therapy could offer benefits in terms of overcoming resistance to individual agents.
The first randomised phase III study that investigated sequential targeted therapy in mRCC compared the mTOR inhibitor everolimus versus placebo in patients who had progressed on sunitinib, sorafenib or both. 55 syndrome. 70 The combination of sunitinib and bevacizumab was shown to cause a high degree of hypertension and vascular and haematological toxicities in patients with mRCC, also raising doubts about this regimen in this setting. 71 Combination regimens of VEGF-targeted agents and mTOR kinase inhibitors are being investigated in an effort to attain synergistic antitumour activity or to prevent the development of cross-resistance.
The combination of standard doses of everolimus and bevacizumab has demonstrated efficacy and tolerability in both untreated mRCC patients and those previously treated with sorafenib in a phase II study; ORR was similar in both groups of patients (untreated 30%, previously treated 23%).
72
Temsirolimus and bevacizumab in combination was active and tolerable at recommended doses in mRCC, 73 although temsirolimus in combination with sunitinib or sorafenib was associated with excessive toxicity at the doses tested in phase I studies. 74, 75 Additional larger studies are needed to fully elucidate the efficacy and safety of combination regimens of targeted agents in mRCC.
Integrating Surgical and Targeted Therapies

Neoadjuvant Targeted Therapy
Neoadjuvant strategies that integrate surgical intervention with systemic therapy may hold promise as a treatment paradigm in mRCC. 76 The utility of pre-operative systemic therapy for tumour downsizing has not been explored extensively owing to the rare objective responses to cytokine therapy. However, the efficacy of 
Conclusions
Clinical studies have validated the utility of targeted inhibitors of the VEGF and mTOR pathways for treatment of mRCC, significantly improving the prognosis for many patients. Furthermore, the generally favourable toxicity profile of these agents renders them more appealing than previously used cytokine therapies. Ongoing research is focusing on identifying the optimal sequence and combinations of these agents, together with the potential role for targeted agents in the adjuvant and neoadjuvant settings. 
